Jardiance, Farxiga are the first drugs to complete PDAB’s cost review process, clearing the way for board to take steps to bring costs down
July 29, 2025
Maryland Matters
Danielle J. Brown
Excerpt:
Vincent DeMarco, a long-time supporter of the board’s effort and president of the Maryland Health Care for All Coalition, called the preliminary decision a “really big deal.”
In a written statement, the coalition commended board members for agreeing that the “critically-needed diabetes drugs” can cause an affordability challenge for the state, and expressed hope that the board will quickly make decisions to bring those costs down.
The preliminary determination allows the board to consider options for reducing spending on those drugs for the state, including the possible use of upper payment limits to cap how much the state is willing to pay for them.
Read the full article at MarylandMatters.org.
